Retatrutide (Triple-G): Next-Gen Weight Loss Peptide Guide for UAE (2026)

What Is Retatrutide?

Retatrutide (development code: LY3437943) is an investigational peptide drug developed by Eli Lilly and Company. Unlike earlier weight-loss drugs that target a single receptor, retatrutide simultaneously activates three receptors:

• GLP-1 receptor (glucagon-like peptide-1) — reduces appetite, slows gastric emptying
• GIP receptor (glucose-dependent insulinotropic polypeptide) — improves insulin sensitivity, amplifies GLP-1 effects
• Glucagon receptor — increases energy expenditure (thermogenesis), drives fat oxidation in the liver

This triple mechanism — commonly called "Triple-G" — produces weight loss effects that exceed any single- or dual-agonist approach. In June 2023, Phase 2 trial results published in the New England Journal of Medicine showed participants on the highest dose of retatrutide lost an average of 24.2% of their body weight over 48 weeks — the highest weight-loss efficacy ever recorded for an injectable anti-obesity medication in a randomized controlled trial.

Retatrutide vs Semaglutide vs Tirzepatide

The critical distinction: retatrutide achieved 24.2% weight loss in 48 weeks, while tirzepatide's 22.5% required 72 weeks. The rate of weight loss with retatrutide is significantly faster, and weight loss curves had not plateaued at 48 weeks in the higher dose groups.

How the Triple-G Mechanism Works

GLP-1 Receptor Activation

GLP-1 agonism reduces appetite by acting on hypothalamic satiety centers, slows gastric emptying (creating prolonged fullness), and stimulates insulin release in a glucose-dependent manner. This is the mechanism shared by semaglutide and tirzepatide.

GIP Receptor Activation

GIP amplifies GLP-1's insulinotropic effect and has direct effects on adipose tissue — promoting fat mobilization from fat cells. Combined with GLP-1, it produces synergistic weight loss beyond either alone, as established by tirzepatide's superiority over semaglutide.

Glucagon Receptor Activation

This is retatrutide's differentiating feature. Glucagon increases energy expenditure (metabolic rate), drives hepatic fat oxidation, and reduces liver fat content. Traditional thinking held that glucagon agonism would impair diabetes control by raising blood sugar — but when balanced with GLP-1 and GIP's insulin-stimulating effects, the glycemic impact is neutral while the fat-burning effect remains fully additive.

The glucagon component makes retatrutide especially promising for fatty liver disease (NAFLD/NASH) — affecting an estimated 30-40% of UAE adults. Phase 2 data showed retatrutide reduced liver fat content by over 80% in NAFLD subjects.

Phase 2 Clinical Trial Results

The pivotal Phase 2 study (Jastreboff et al., NEJM June 2023) enrolled 338 adults with obesity across dose groups over 48 weeks:

• Placebo: +2.1% weight change
• Retatrutide 1mg/week: -8.7%
• Retatrutide 4mg/week: -17.1%
• Retatrutide 8mg/week: -17.5%
• Retatrutide 12mg/week: -24.2%

Weight loss curves had not plateaued at 48 weeks for the higher dose groups, suggesting potential for even greater outcomes with longer treatment duration.

Retatrutide Dosage Protocol

Based on Phase 2 trial titration schedules:

• Starting dose: 0.5mg once weekly (subcutaneous injection)
• Titration: Increase by 0.5-1mg every 4 weeks based on tolerability
• Effective range: 4-8mg weekly
• Maximum dose (trial): 12mg weekly
• Administration: Once weekly subcutaneous injection into abdomen, thigh, or upper arm

Side Effects & Safety

Side effects in Phase 2 trials were primarily gastrointestinal and dose-dependent:

• Nausea: 45% of participants (most common during titration)
• Vomiting: 23%
• Diarrhea: 18%
• Constipation: 14%
• Decreased appetite: near-universal (mechanism of action)

GI side effects typically peak during dose escalation and diminish after 4-6 weeks at a stable dose. Serious adverse events were rare (<2%) and not significantly different from placebo. No cases of pancreatitis or thyroid cancer were reported in Phase 2 trials.

Managing Side Effects

• Slow dose titration is critical — starting at 0.5-1mg and escalating gradually
• Ensure adequate hydration and electrolyte intake
• Maintain protein intake above 1.5g/kg to minimize muscle loss
• Resistance training 3-4x per week helps preserve lean mass

Preserving Muscle Mass on Retatrutide

All GLP-1-based drugs carry risk of lean mass loss alongside fat loss. For retatrutide at 24% body weight reduction, this is a significant concern for athletes in the UAE fitness community.

Recommended muscle preservation strategies:

• Resistance training minimum 3-4x per week
• Protein intake: 1.8-2.2g per kg of body weight daily
• Consider stacking with GH-stimulating peptides: MK-677 or CJC-1295/Ipamorelin

See: MK-677 Complete Guide for UAE and CJC-1295 + Ipamorelin Stack.

Retatrutide for NAFLD in UAE

Non-alcoholic fatty liver disease (NAFLD) affects an estimated 30-40% of UAE adults — one of the highest rates globally, driven by sedentary lifestyles, high-caloric diets, and metabolic syndrome prevalence. Retatrutide's glucagon component targets hepatic fat directly:

Phase 2 data showed retatrutide reduced liver fat content (measured by MRI-PDFF) by 81.7% at 48 weeks, versus approximately 70% for tirzepatide in NAFLD studies. For UAE residents with concurrent obesity and fatty liver, retatrutide represents a potentially transformative research compound.

Retatrutide in Dubai & UAE: Current Status

Retatrutide is in Phase 3 global clinical trials and not yet approved by any regulatory authority including UAE's MOHAP. As a research chemical, it is available for investigational use in the UAE.

Dubai's sophisticated healthcare infrastructure and growing medical wellness sector position it well for early access to emerging metabolic therapies. Clinics offering metabolic optimization services across Dubai and Abu Dhabi are closely monitoring retatrutide's Phase 3 progress.

Retatrutide vs Mounjaro: Which Is Right for You?

Mounjaro (tirzepatide) is the current gold-standard approved weight-loss injectable available in UAE pharmacies. The practical decision:

• Mounjaro: MOHAP-approved, clinical physician oversight available, established safety record, 22.5% weight loss over 72 weeks
• Retatrutide: Research peptide, higher efficacy potential (24.2% in 48 weeks), superior for fatty liver, investigational status only
• Choose based on: Regulatory preference, liver health status, and weight loss targets

Read: Mounjaro/Tirzepatide Dubai and UAE Guide.

Where to Research Retatrutide in UAE

CoreSup provides research-grade retatrutide for investigational use, with delivery across Dubai, Abu Dhabi, and the wider UAE. All products include certificate of analysis (CoA) for purity verification.

Browse research peptides at CoreSup — UAE's trusted research compound supplier.

Frequently Asked Questions

What is retatrutide?

Retatrutide (LY3437943) is a triple agonist peptide by Eli Lilly activating GLP-1, GIP, and glucagon receptors. Phase 2 trials showed up to 24.2% body weight loss at 48 weeks.

How much weight can you lose with retatrutide?

Up to 24.2% body weight loss at 48 weeks (12mg/week dose) — the highest efficacy ever recorded for an injectable weight-loss drug in clinical trials.

How does retatrutide differ from tirzepatide?

Tirzepatide is dual GLP-1 + GIP. Retatrutide adds glucagon receptor activation (Triple-G), increasing energy expenditure and hepatic fat oxidation — producing faster, greater weight loss and superior liver fat reduction.

Is retatrutide approved?

No — in Phase 3 trials as of 2026. Available as a research peptide for investigational use in the UAE.

What are retatrutide side effects?

Primarily GI: nausea (45%), vomiting (23%), diarrhea (18%). Dose-dependent and typically reduce after the titration period.

Where can I get retatrutide in UAE?

Available as a research peptide through CoreSup (coresup.shop) with purity certificates for UAE delivery.